Archive · 22 Sep 2025
Alkem Launches Affordable Pertuzumab Biosimilar for Breast Cancer
Alkem Laboratories has introduced an affordable version of a medicine called pertuzumab, now available as an injection, for women in India who have a specific type of breast cancer.
This medicine is designed to help patients with HER2-positive breast cancer, which is a type of cancer.
The new medicine, made in India, has shown similar effectiveness and safety as the original.
Alkem aims to make this medicine easier to get because the original one was too expensive for many.
The company has already launched other similar medicines for cancer treatment.
The CEO says their goal is to provide effective and accessible treatments.
Alkem Laboratories launched a pertuzumab biosimilar.
The biosimilar is for treating HER2-positive breast cancer.
The product is indigenously developed and aims to be affordable.
Clinical trials showed the biosimilar's equivalence to the reference product.
Alkem aims to improve access to the treatment.
- Who
- Alkem Laboratories Ltd
- What
- Launched a biosimilar version of pertuzumab for breast cancer treatment.
- When
- Published on September 22, 2025
- Where
- India
- Why
- To improve access to affordable treatment for HER2-positive breast cancer patients.
Patients with HER2-positive breast cancer
Patients with HER2-positive breast cancer
Access to Treatment
Patients with HER2-positive breast cancer
The introduction of affordable biosimilars can improve access.
Patients with HER2-positive breast cancer
The introduction of affordable biosimilars can improve access.
- Company
- Alkem Laboratories Ltd
- Product
- Pertuza injection (pertuzumab biosimilar)
- Purpose
- Treatment of HER2-positive breast cancer
- Key Benefit
- Affordability and improved access
- Development Status
- Indigenously developed
- Clinical Trial Result
- Equivalence to reference product
- Other Biosimilars in Portfolio
- Cetuximab, Denosumab, Bevacizumab, Romiplostim
- CEO
- Dr. Vikas Gupta